Harry Perkins Institute of Medical Research
6 Verdun Street
Nedlands, WA 6009
Australia
61 8 6151 0992
https://pyctx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Executive Director | 437.5k | N/A | 1983 |
Mr. Andrew Taylor B.Com., C.A. | CFO & Company Secretary | N/A | N/A | N/A |
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary | 165.9k | N/A | 1962 |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.